SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Journal of Pharmacy Practice
This Article
Right arrow Full Text (OnlineFirst PDF)
Right arrow All Versions of this Article:
0897190008326104v1
22/2/179    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Cheng, J. W. M.
Right arrow Articles by Goldman-Levine, J. D.
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Article

The Benefit and Risk of Antidiabetic Agents Used in Patients With Heart Disease

Judy W. M. Cheng, BS, PharmD, MPH, FCCP, BCPS*, Snehal H. Bhatt, PharmD, BCPS, and Jennifer D. Goldman-Levine, PharmD, CDE

* To whom correspondence should be addressed. E-mail: judy.cheng{at}mcphs.edu.


  Abstract
Diabetes increases the risk of cardiovascular diseases. While improving glycemic control has been demonstrated to reduce microvascular complications, the benefits in reducing macrovascular complications have been controversial. This article reviews the published evidence assessing the benefits and risk of antidiabetic agents as related to cardiovascular outcomes. Current literature revealed that metformin and {alpha}-glucosidase inhibitors are the two agents that have not been associated with any harm in diabetic patients in terms of cardiovascular events. Clinical studies have demonstrated controversial results in the use of insulin, sulfonylureas, and thiazolidinediones and cardiovascular outcomes. However, the results may be affected by other unknown confounders, the comparative agents, and the degree of control of other cardiovascular risk factors. Clinicians should choose antidiabetic therapy based on patient specific parameters such as current glycemic control, and other concurrent disease states such as heart failure.

First published on November 4, 2008, doi:10.1177/0897190008326104

Journal of Pharmacy Practice 2009;22:179.

A more recent version of this article appeared on April 1, 2009

Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?




Advertisement